XENE Azetukalner NDA for Focal Seizures, Depression Paused

Xenon Pharmaceuticals (Nasdaq: XENE) filed its first New Drug Application, submitting azetukalner as an adjunctive treatment for focal seizures in adults. In the same September 17 release, the company disclosed a voluntary pause on new-patient enrollment across its depression and bipolar studies after an analysis of neuropsychiatric adverse events, a signal that had not appeared in earlier trials.

Azetukalner is a KV7 potassium channel opener. It opens potassium channels in neurons, reducing the excessive firing that drives seizures, and it would be the first drug of that mechanism to reach the FDA for epilepsy. The NDA rests on two randomized trials, the Phase 2b X-TOLE and Phase 3 X-TOLE2 studies. In X-TOLE2, which enrolled 380 patients, the 25 mg dose cut median monthly focal seizure frequency by 53.2% and the 15 mg dose by 34.5%, against 10.4% for placebo (P<.001 for both). The safety database spans more than 1,500 patient-years, with dizziness the most common side effect at 20.5% versus 3.2% for placebo.

The market gap is real. Epilepsy affects roughly 3 million US adults, and even with more than 30 approved treatments, up to half of people with focal epilepsy still have uncontrolled seizures. Xenon’s pitch is that a new mechanism, distinct from the older sodium-channel and GABA drugs, can be layered onto existing therapy without dose adjustments.

The psychiatry pause is the counterweight. The neuropsychiatric events were consistent with the drug’s known profile, Xenon said, but had not been seen in the Phase 2 X-NOVA depression study. The company paused enrollment in its MDD and bipolar studies in consultation with its data safety board and now expects X-NOVA2 topline results in the first quarter of 2027, a delay from prior guidance. Patients already enrolled will continue on study.

The market read the release as a net negative. XENE closed at $36.94 on September 25, down about 31% from the roughly $53 it traded at before the announcement, leaving the epilepsy NDA as the sole near-term driver and the depression upside on hold. The same KV7 mechanism underpins Biohaven’s opakalim program, which Biohaven licensed to SK Biopharmaceuticals for up to $795 million in August.

What to watch next is the FDA’s decision to accept the filing and assign a PDUFA date, the first hard deadline on Xenon’s path to its first approval. See the earlier piece on the KV7 licensing deal that validated this mechanism. Read Xenon’s full announcement here.

What It Means for the Trade

The 31% drawdown is the market telling you the depression pipeline was priced in and the epilepsy NDA was not. That reframes the stock: XENE now trades as a single-asset epilepsy story with optionality, and the near-term catalyst is procedural — the FDA’s filing-acceptance decision and PDUFA date assignment, the first hard deadline on the path to Xenon’s first approval. The efficacy data supports the case: 53.2% median seizure-frequency reduction at 25 mg against 10.4% for placebo, with more than 1,500 patient-years of safety database, is registrational-grade for a focal epilepsy adjunct. The market is real — up to half of focal epilepsy patients stay uncontrolled on 30-plus approved drugs, and a first-in-mechanism KV7 opener that layers onto existing therapy without dose adjustments addresses exactly that population. The psychiatry program is not dead, but it is now a 2027 story at the earliest: X-NOVA2 topline slipped to the first quarter of 2027, and any re-rating depends on the safety analysis clearing. Position accordingly — the binary is epilepsy, and the psychiatry optionality is currently priced near zero.

Mechanism and Market Context

Azetukalner opens KV7 potassium channels, calming the neuronal hyperexcitability that drives seizures — a mechanism genuinely distinct from the sodium-channel and GABA drugs that dominate the epilepsy cabinet. The same mechanism’s validity was just third-party confirmed: Biohaven licensed its KV7 opakalim program to SK Biopharmaceuticals for up to $795 million in August, which puts a market value on the class independent of Xenon’s own data. The neuropsychiatric signal that paused the psychiatry studies is the flip side of a CNS-active mechanism, which is why the DSMB consultation and the enrollment pause matter for how regulators read the epilepsy filing.

Risks and What Could Go Wrong

1. The FDA could refuse the filing or attach psychiatry-relevant labeling language even to the epilepsy indication.
2. The neuropsychiatric events, while consistent with the known profile, had not appeared in earlier trials — the analysis is unresolved.
3. Dizziness at 20.5% versus 3.2% placebo could show up in labeling and slow adoption.
4. X-NOVA2’s slip to Q1 2027 leaves a long news gap, and the stock has already shown what an empty catalyst calendar does to it.